A pilot trial assessing the effect of fish oil on leptin and adiponectin levels in overweight/obese individuals.

A pilot trial assessing the effect of marine lipids on leptin and adiponectin levels in overweight/obese individuals.

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12610000983000

Enrollment

Registered

2010-11-15

Start date

2010-11-08

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Obesity is a global epidemic. It is associated with a high burden of chronic diseases such as type 2 diabetes mellitus (T2DM), cardiovascular disease (CVD) and some cancers. Obesity and CVD progression have been associated with altered levels of biologically active proteins secreted by adipocytes, including the hormones adiponectin and leptin. This study aims to assess the effect of a high dose marine lipid supplement [dose: 4000mg per day for 8 weeks] on plasma adiponectin and leptin levels in overweight and obese individuals.

Interventions

Treatment with commercially available marine lipid preparation at a dose of 4 x 1000mg capsules per day (each capsule contains 300mg EPA, 200mg DHA) for a period of 8 weeks

Study design

Allocation

Non-randomised trial

Primary purpose

Prevention

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Participants will have a BMI of 25 or greater and be generally healthy.

Exclusion criteria

Concurrent use of other medications or investigational products; Weight loss of more than 10% body weight within the last six months; Active substance abuse (alcohol or drug dependency); Breast feeding or pregnancy; Smoking; Allergies to fish oil supplements; Major Health Conditions; Concomitant use of anticoagulants or statin medications (Pravastatin).

Outcome results